Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 12

1.

Regulatory withdrawal of medicines marketed with uncertain benefits: the bevacizumab case study.

Vitry A, Nguyen T, Entwistle V, Roughead E.

J Pharm Policy Pract. 2015 Oct 19;8:25. doi: 10.1186/s40545-015-0046-2. eCollection 2015.

2.

The diffusion of docetaxel in patients with metastatic prostate cancer.

Unger JM, Hershman DL, Martin D, Etzioni RB, Barlow WE, LeBlanc M, Ramsey SR.

J Natl Cancer Inst. 2014 Dec 24;107(2). pii: dju412. doi: 10.1093/jnci/dju412. Print 2015 Feb.

3.

Delivering high-quality and affordable care throughout the cancer care continuum.

Shih YC, Ganz PA, Aberle D, Abernethy A, Bekelman J, Brawley O, Goodwin JS, Hu JC, Schrag D, Temel JS, Schnipper L.

J Clin Oncol. 2013 Nov 10;31(32):4151-7. doi: 10.1200/JCO.2013.51.0651. Epub 2013 Oct 14.

4.

Promise and perils of guidelines in quality cancer care.

Irwin B, Peppercorn J.

J Oncol Pract. 2012 Nov;8(6):354-7. doi: 10.1200/JOP.2012.000618. Epub 2012 Jul 17. No abstract available.

5.

Conflict of interest disclosure in off-label oncology clinical trials.

Irwin B, Hirsch BR, Samsa GP, Abernethy AP.

J Oncol Pract. 2012 Sep;8(5):298-302. doi: 10.1200/JOP.2011.000523. Epub 2012 Jun 26.

6.

Unsupported off-label chemotherapy in metastatic colon cancer.

de Souza JA, Polite B, Perkins M, Meropol NJ, Ratain MJ, Newcomer LN, Alexander GC.

BMC Health Serv Res. 2012 Dec 29;12:481. doi: 10.1186/1472-6963-12-481.

7.

Cost, coverage, and comparative effectiveness research: the critical issues for oncology.

Pearson SD.

J Clin Oncol. 2012 Dec 1;30(34):4275-81. doi: 10.1200/JCO.2012.42.6601. Epub 2012 Oct 15. Review.

9.

Commentary: should cost and comparative value of treatments be considered in clinical practice guidelines?

Basch E, Somerfield MR, Partridge A, Schnipper L, Lyman GH.

J Oncol Pract. 2011 Nov;7(6):398-401. doi: 10.1200/JOP.2011.000414. Epub 2011 Oct 18. No abstract available.

10.

Off-label use of rituximab in a multipayer insurance system.

Van Allen EM, Miyake T, Gunn N, Behler CM, Kohlwes J.

J Oncol Pract. 2011 Mar;7(2):76-9. doi: 10.1200/JOP.2010.000042.

11.

Type of evidence behind point-of-care clinical information products: a bibliometric analysis.

Ketchum AM, Saleh AA, Jeong K.

J Med Internet Res. 2011 Feb 18;13(1):e21. doi: 10.2196/jmir.1539.

12.

Off-label prescribing: a call for heightened professional and government oversight.

Dresser R, Frader J.

J Law Med Ethics. 2009 Fall;37(3):476-86, 396. doi: 10.1111/j.1748-720X.2009.00408.x.

Supplemental Content

Support Center